mHSPC COE

VA Study Examines Use of Combination Therapies for mHSPC and Outcomes in Patients - Martin Schoen & Bruce Montgomery Details Neeraj Agarwal leads a discussion with Martin Schoen and Bruce Montgomery about a study examining treatment patterns and outcomes for veterans with metastatic hormone-sensitive prostate cancer. The research reveals that VA patients demonstrate longer survival rates compared to the general U.S. population, particularly among younger patients, with combination therapy now being utilized in approxima...
Introduction to mHSPC – What Are Relevant Prognostic/Predictive Factors for the Management of Patients? "Presentation" - Matthew Smith Details At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Matthew Smith presents an overview of prognostic and predictive biomarkers in metastatic castration-sensitive prostate cancer, examining established factors like disease patterns and volume while highlighting the Decipher score's prognostic value. Biographies: Matthew Smith, MD, PhD, Oncologist, Professor of Medicine, Harvard Medic...
Synchronous Low-Volume mHSPC – in Which Patients Do You Recommend Combination Systemic Therapy plus Local Treatment of the Primary and in Which Patients Is ADT Alone plus RT Enough? "Presentation" - R... Details At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Robert Jones discusses the role of combination therapy in low-volume metastatic prostate cancer, examining evidence from PEACE-1 and meta-analyses that suggest potential benefits of triplet therapy (radiotherapy + ARPI + ADT) over doublet options despite not reaching statistical significance. Biographies: Robert Jones, PhD, Profess...
In Which Patients with Synchronous Low-Volume mHSPC Do You Recommend “Total Therapy”? "Presentation" - Oliver Sartor Details At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Oliver Sartor discusses the management of synchronous, low-volume, metastatic hormone-sensitive prostate cancer. The presentation analyzes data from major trials like PEACE-1 and ARASENS while addressing the benefits of prostate radiation and acknowledging the complexity of real-world treatment decisions. Biographies: Oliver Sartor...
Which Patients with mHSPC Should Get Triplet Systemic Therapy: ADT plus Docetaxel plus ARPI? "Presentation" - Nicholas James Details At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Nicholas James presents an analysis of triplet therapy in prostate cancer treatment, examining evidence from the PEACE-1, ARASENS, and ENZAMET trials. Through network meta-analysis, he explores the comparative effectiveness of different treatment combinations and proposes a framework based on disease characteristics. Biographies: N...
Should the Primary be Treated in Synchronous High-Volume mHSPC? "Presentation" - Sandy Srinivas Details At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Sandy Srinivas examines the role of radiation therapy to the primary tumor in metastatic prostate cancer. The presentation questions whether overall survival should be the sole metric for evaluating interventions. Biographies: Sandy Srinivas, MD, Oncologist, Professor of Medicine (Oncology), Stanford University, Palo Alto, CA Relat...
Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice? "Presentation" - Michael Morris Details At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Michael Morris presents a critical examination of optimal imaging standards for metastatic hormone-sensitive prostate cancer. The presentation explores PSMA imaging's potential while acknowledging its complications such as flare phenomenon and PSMA downregulation. Biographies: Michael Morris, MD, Prostate Cancer Section Head, GU On...
Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? "Presentation" - Bertrand Tombal Details At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal examines treatment de-escalation strategies in metastatic hormone-naive prostate cancer. He explores three main approaches: stopping ADT while continuing ARPI, stopping ARPI while maintaining ADT, and revisiting intermittent androgen deprivation therapy, and emphasizes the importance of clinical trials like the P6 p...
How to Manage Patients with Low-Volume on Conventional and High-Volume on NGI "Presentation" - Dana Rathkopf Details At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Dana Rathkopf addresses the complex challenge of managing prostate cancer patients who show low-volume disease on conventional imaging but high-volume disease on next-generation PET imaging. The presentation explores evidence suggesting PET-only metastases may be more indolent than conventional imaging-visible disease. Biographies:...
Management of Patients with mHSPC and Early Progression on Combination Therapy "Presentation" - Christopher Sweeney Details At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Christopher Sweeney discusses strategies for managing early progression after combination therapy in prostate cancer. He emphasizes the importance of proper patient and tumor profiling while presenting ENZAMET trial data showing survival differences based on progression patterns. Biographies: Christopher Sweeney, MBBS, Professor of...

mHSPC COE

Login